Works matching IS 01145916 AND DT 2019 AND VI 42 AND IP 2
Results: 11
Safety and Tolerability of Antibody-Drug Conjugates in Cancer.
- Published in:
- 2019
- By:
- Publication type:
- journal article
Safety and Tolerability of Histone Deacetylase (HDAC) Inhibitors in Oncology.
- Published in:
- 2019
- By:
- Publication type:
- journal article
Safety and Tolerability of c-MET Inhibitors in Cancer.
- Published in:
- 2019
- By:
- Publication type:
- journal article
Safety and Tolerability of Adoptive Cell Therapy in Cancer.
- Published in:
- 2019
- By:
- Publication type:
- journal article
Safety and Tolerability of Anti-Angiogenic Protein Kinase Inhibitors and Vascular-Disrupting Agents in Cancer: Focus on Gastrointestinal Malignancies.
- Published in:
- 2019
- By:
- Publication type:
- journal article
Safety and Tolerability of Phosphatidylinositol-3-Kinase (PI3K) Inhibitors in Oncology.
- Published in:
- 2019
- By:
- Publication type:
- journal article
Safety and Tolerability of Sonic Hedgehog Pathway Inhibitors in Cancer.
- Published in:
- 2019
- By:
- Publication type:
- journal article
Safety and Tolerability of Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors in Oncology.
- Published in:
- 2019
- By:
- Publication type:
- journal article
Safety and Tolerability of Anaplastic Lymphoma Kinase Inhibitors in Non-Small-Cell Lung Cancer.
- Published in:
- 2019
- By:
- Publication type:
- journal article
Safety of Novel Targeted Therapies in Oncology.
- Published in:
- 2019
- By:
- Publication type:
- Editorial
Safety and Tolerability of Immune Checkpoint Inhibitors (PD-1 and PD-L1) in Cancer.
- Published in:
- 2019
- By:
- Publication type:
- journal article